Smartphone based therapy management is the future of diabetes treatment. Combine the mylife YpsoPump insulin pump, the mylife CamAPS FX mobile application and the Dexcom G6 Continuous Glucose Monitoring (CGM) System for an automated insulin delivery system managed directly from your smartphone. The integration of automated insulin delivery into the mylife YpsoPump system portfolio allows you time away from your diabetes and more freedom to do what you love doing.

How mylife Loop works

For automated insulin delivery with the mylife YpsoPump you need the mylife CamAPS FX app and the Dexcom G6 CGM System. Connect the mylife CamAPS FX app to the insulin pump and the Dexcom G6 sensor. The Dexcom G6 sensor sends glucose data every five minutes to the mylife CamAPS FX app. Based on those readings, the app adjusts insulin delivery on the insulin pump every eight to twelve minutes to prevent low and high glucose levels.

The mylife CamAPS FX app is personalised and adaptive; it constantly learns and quickly adapts to ever changing insulin needs. It adjusts to diurnal and day-to-day variations in insulin requirements and compensates for over and under-dosing of the meal bolus. For increased privacy and convenience, you are able to deliver a meal bolus directly from your smartphone.

mylife Loop - CamAPS Video

mylife CamAPS FX is currently not approved in Canada*.

mylife CamAPS FX How does it learn?

CamAPS FX - Learning mylife CamAPS FX is currently not approved in Canada*.

mylife CamAPS FX is currently not approved in Canada*.

Prof. Roman Hovorka, developer of the mylife CamAPS FX app, explains how the mylife CamAPS FX algorithm learns.

The learning takes place on three levels:

Level 1
Overall learning: This learning is based on the body’s overall insulin need: the insulin needed on average and during the day.

Level 2
Diurnal learning (over 24 hours): This learning is based on how much insulin is needed for a specific hour in a day. 

Level 3
Post-meal learning: When the user delivers a meal bolus, the system will observe whether the insulin amount was appropriate. If a user constantly over or underestimates carbohydrates, the system will start to adjust insulin delivery post-meal.

All these learnings are occurring continuously.

Specifications mylife CamAPS FX

Screen overview

Navigation (Home screen)
Home screen
Detailed graph (to view the detailed graph rotate the home screen into landscape configuration or tap the "screen rotation" icon).

Main features

Overview of the mylife CamAPS FX app specifications.
Phone compatibility: Android smartphones compatible with Dexcom:

For Companion remote monitoring only: Android smartphones running OS 8 and above.
Compatible CGM (Continuous Glucose Monitoring) sensor: Dexcom G6: factory calibrated, blood glucose tests only needed in exceptional cases (consult the Dexcom G6 Instructions for Use)
Total daily dose (TDD) and weight range: 5-350 units/day total daily insulin (TDD)
10-300 kg weight
Algorithm: Treat to target
Predictive control (the algorithm calculates the insulin requirement for the next 2.5-4 hours)
Adaptive model (insulin delivery is adjusted every 8-12 minutes)
Learning: Continually adjusting insulin delivery every 8-12 minutes based on CGM glucose data received every 5 minutes. Learning from previous insulin delivery and meal bolus information to adapt to diurnal, day-to-day as well as post-meal insulin needs.
Glucose target: Default target: 5.8 mmol/L
Customisable personal target: 4.4-11.0 mmol/L
Data sharing: Yes, via:
mylife CamAPS FX app on smartphone: generation and export of PDF reports including glucose statistics, insulin statistics, "Auto mode" and alert statistics, information about settings and weekly overviews. Internet connectivity is required to generate PDF reports.

Glooko: automated data upload from the mylife CamAPS FX app to the Glooko platform to share data with healthcare professionals. Internet connectivity is required to share data with Glooko.
Remote monitoring: Yes, via:
Companion remote monitoring: the mylife CamAPS FX app allows user's data to be shared with up to 10 "companions". Remote monitoring is integrated into the app and therefore both, user and "companion", use the mylife CamAPS FX app. CGM data, insulin data and other data as well as alerts are mirrored in the "companion's" mylife CamAPS FX app. Internet connectivity is required to share data with "companions".

SMS based remote monitoring: the mylife CamAPS FX app supports SMS based remote monitoring. All app generated alarms and alerts will be sent via SMS message to up to 5 "followers". A SIM card is required to send SMS messages to "followers".

Please note that it is possible to use the Companion remote monitoring and SMS based remote monitoring at the same time.
Discrete bolusing: Yes, via mylife CamAPS FX app on smartphone
Bolus suggestion calculator: Yes, via mylife CamAPS FX app on smartphone
Additional features: “Boost” and “Ease-off” modes
Slowly absorbed meal function

Clinical benefits

Overall acceptance across all age groups

There is an overall acceptance of the closed-loop approach across all age groups: pre-schoolers1, children2,3,4, adolescents2,3,4, adults2,3 and older adults5. Reduced burden of diabetes and improved quality of life in children, adolescents and adults were observed2. Psychosocial benefits reported by parents and caregivers included improved sleep, improved quality of life, and reduced burden of diabetes6. Closed-loop is also a safe and clinically important treatment option for older adults5.

The use of CamAPS FX in young children aged 1 to 7 years documented clinically and statistically significant reduction of HbA1c by 0.4%, and an increase in time in target glucose range by 9% without increasing time in hypoglycaemia below 3.9 mmol/L1.

The use of the CamAPS FX control algorithm in people aged 6 years and older, including adults, resulted in reduction of HbA1c by 0.4%, increased time in target glucose range by 11%, and reduced time in hypoglycaemia below 3.9 mmol/L by 0.8%3. This demonstrates the importance and the ability of the CamAPS FX control algorithm to achieve desirable glucose control safely.

The comparator in both studies was sensor augmented pump therapy applying identical insulin pump and identical glucose sensor but not using the control algorithm.

Read about Emmie’s experience with the automated insulin delivery system mylife Loop .

Parents and caregivers can have peace of mind thanks to remote monitoring

Control and monitoring of blood sugar, especially overnight, is a relief and leads to a better night’s sleep. The burden of diabetes for parents and caregivers is reduced significantly and they feel less worried about their child’s glucose control. In general, users are able to spend less time managing their diabetes.6

Improved glucose control during pregnancy

Closed-loop insulin delivery was associated with comparable glucose control and significantly less hypoglycaemia than sensor augmented pump therapy. Moreover, closed-loop insulin delivery was reported as safe and could effectively control glucose levels in a broad range of pregnant women with type 1 diabetes.7

Closed-loop performed well during labour and delivery. The system adapted quickly to the rapid change in insulin requirements after delivery, with women spending over 80% time in target glucose range in the immediate postpartum period.8

Improved quality of life thanks to an adaptive and self-learning automated insulin delivery system

The mylife CamAPS FX app constantly learns and quickly adapts to ever changing insulin needs. It adjusts to diurnal and day-to-day variations in insulin requirements and compensates for over and under-dosing of meal bolus. If a user consistently over or underestimates carbohydrates, the algorithm adjusts insulin delivery accordingly, to prevent low and high glucose levels. This enables safe and efficient use in all life circumstances2.

Full flexibility with "Boost" and "Ease-off" modes

Are you planning to exercise? Is it hot outside? The "Ease-off" mode reduces insulin delivery depending on glucose levels, raises the glucose target temporarily and stops insulin delivery if your glucose level is predicted to fall below target. On the flip side, you are also able to "Boost" to make the algorithm more responsive and to increase insulin delivery by ~35%. This can come in handy if you happen to miss a bolus or when your period is due. Once glucose reaches your target, the "Boost" mode will not push glucose lower than your target.

Truly personalised diabetes management

Do you need to go higher in the morning and lower in the afternoon with your glucose levels? You can adjust your own personal target between 4.4-11.0 mmol/L in 30 minute segments. Furthermore, with the slowly absorbed meal function, the algorithm will deliver extra insulin over 3-4 hours, depending on glucose levels.

What mylife Loop users say

I can’t imagine having such an active lifestyle without the mylife Loop. I have three children and enjoy regular exercise. I am so grateful I now have more time to enjoy the beautiful things in life.

Kathi, diagnosis at 21

I love how the app algorithm started to recognise the patterns in my blood sugars and works to keep me in range. But the best thing for me was finally getting a full night’s sleep.

Oisin, diagnosis at 9

Having more stable blood glucose and better time in range makes everyday life easier.

Susanne, diagnosis at 38

Stay in the Loop

Stay informed about our mylife Loop? Fill out the form below and we promise to keep you in the Loop.

Your contact details

We only use the data you provide us on this form for the above-mentioned purpose. We do not save the data on this web server. For more information on the collection and processing of your data, please refer to our Privacy Policy.

Please add 2 and 1.

* Mandatory fields

Referenced clinical studies

1 Ware J. et al.: Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
N Engl J Med. 2022 Jan;386(3):209-219. DOI: 10.1056/NEJMoa2111673

2 Barnard K. D. et al.: Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy.
J Diabetes Sci Technol. 2017 Nov;11(6):1080-1088. DOI: 10.1177/1932296817702656

3 Tauschmann M. et al.: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 Oct;392(10155):1321-1329. DOI: 10.1016/S0140-6736(18)31947-0

4 Ware J. et al.: Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health. 2022 Apr;4(4):e245-e255. DOI:10.1016/ S2589-7500(22)00020-6

5 Boughton C. K. et al.: Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Healthy Longev. 2022 Mar;3(3):e135–e142. DOI: 10.1016/S2666-7568(22)00005-8

6 Musolino G. et al.: Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes. Pediatr Diabetes. 2019 Sep;20(6):794-799. DOI: 10.1111/pedi.12872

7 Stewart Z. A. et al.: Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care. 2018 Jul;41(7):1391-1399. DOI: 10.2337/dc17-2534

8 Stewart Z. A. et al.: Adaptability of Closed Loop During Labor, Delivery, and Postpartum: A Secondary Analysis of Data from Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. Diabetes Technol Ther. 2018 Jul; 20(7):501-505. DOI: 10.1089/dia.2018.0060



The product images are for illustrative purposes only.

CamAPS FX is a product of CamDiab Limited, Cambridge, UK.

Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license.

Other trademarks and trade names are those of their respective owners.

*The innovation described is available in selected countries and expanding to further countries soon. Expansion is contingent upon Health Canada licensing.

For safety information on mentioned products, see